AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions

Salvatore Petta, Ferruccio Bonino, Fabio Marra, Stefano Bellentani, Gianluca Svegliati-Baroni, Giulio Marchesini, Fabio Nascimbeni, Filomena Morisco, Elisabetta Bugianesi, Giovanni Targher, Amalia Gastaldelli, Fabio Piscaglia, Luca Valenti, Luca Miele, Amedeo Lonardo, Alessandro Casini, Mauro Bernardi

Risultato della ricerca: Article

104 Citazioni (Scopus)

Abstract

This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic âhitsâ. The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed in-depth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (primary liver cancers and extra-hepatic cancers). Moreover, we critically report on the diagnostic role of non-invasive biomarkers, imaging techniques and liver biopsy, which remains the reference standard for diagnosing the disease, but cannot be proposed to all patients with suspected NAFLD. Finally, the management of NAFLD is also reviewed, by highlighting the lifestyle changes and the pharmacological options, with a focus on the innovative drugs. We conclude that the results of ongoing studies are eagerly expected to lead to introduce into the clinical arena new diagnostic and prognostic biomarkers, prevention and surveillance strategies as well as to new drugs for a tailored approach to the management of NAFLD in the individual patient.
Lingua originaleEnglish
pagine (da-a)471-483
Numero di pagine13
RivistaDigestive and Liver Disease
Volume49
Stato di pubblicazionePublished - 2017

Fingerprint

Liver Neoplasms
Fibrosis
Biomarkers
Liver
Metabolic Diseases
Fatty Liver
Cardiomyopathies
Pharmaceutical Preparations
Type 2 Diabetes Mellitus
Non-alcoholic Fatty Liver Disease
Direction compound
Life Style
Cardiac Arrhythmias
Epidemiology
Cardiovascular Diseases
Pharmacology
Inflammation
Biopsy
Genetic Background
Gastrointestinal Microbiome

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cita questo

Petta, S., Bonino, F., Marra, F., Bellentani, S., Svegliati-Baroni, G., Marchesini, G., ... Bernardi, M. (2017). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease, 49, 471-483.

AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. / Petta, Salvatore; Bonino, Ferruccio; Marra, Fabio; Bellentani, Stefano; Svegliati-Baroni, Gianluca; Marchesini, Giulio; Nascimbeni, Fabio; Morisco, Filomena; Bugianesi, Elisabetta; Targher, Giovanni; Gastaldelli, Amalia; Piscaglia, Fabio; Valenti, Luca; Miele, Luca; Lonardo, Amedeo; Casini, Alessandro; Bernardi, Mauro.

In: Digestive and Liver Disease, Vol. 49, 2017, pag. 471-483.

Risultato della ricerca: Article

Petta, S, Bonino, F, Marra, F, Bellentani, S, Svegliati-Baroni, G, Marchesini, G, Nascimbeni, F, Morisco, F, Bugianesi, E, Targher, G, Gastaldelli, A, Piscaglia, F, Valenti, L, Miele, L, Lonardo, A, Casini, A & Bernardi, M 2017, 'AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions', Digestive and Liver Disease, vol. 49, pagg. 471-483.
Petta S, Bonino F, Marra F, Bellentani S, Svegliati-Baroni G, Marchesini G e altri. AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease. 2017;49:471-483.
Petta, Salvatore ; Bonino, Ferruccio ; Marra, Fabio ; Bellentani, Stefano ; Svegliati-Baroni, Gianluca ; Marchesini, Giulio ; Nascimbeni, Fabio ; Morisco, Filomena ; Bugianesi, Elisabetta ; Targher, Giovanni ; Gastaldelli, Amalia ; Piscaglia, Fabio ; Valenti, Luca ; Miele, Luca ; Lonardo, Amedeo ; Casini, Alessandro ; Bernardi, Mauro. / AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. In: Digestive and Liver Disease. 2017 ; Vol. 49. pagg. 471-483.
@article{8f441f9570334084bcb99b34d61d8aaf,
title = "AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions",
abstract = "This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic {\^a}hits{\^a}. The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed in-depth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (primary liver cancers and extra-hepatic cancers). Moreover, we critically report on the diagnostic role of non-invasive biomarkers, imaging techniques and liver biopsy, which remains the reference standard for diagnosing the disease, but cannot be proposed to all patients with suspected NAFLD. Finally, the management of NAFLD is also reviewed, by highlighting the lifestyle changes and the pharmacological options, with a focus on the innovative drugs. We conclude that the results of ongoing studies are eagerly expected to lead to introduce into the clinical arena new diagnostic and prognostic biomarkers, prevention and surveillance strategies as well as to new drugs for a tailored approach to the management of NAFLD in the individual patient.",
keywords = "Diagnosis, Epidemiology, Gastroenterology, Genetics, Hepatology, Management, Natural history, Physiopathology",
author = "Salvatore Petta and Ferruccio Bonino and Fabio Marra and Stefano Bellentani and Gianluca Svegliati-Baroni and Giulio Marchesini and Fabio Nascimbeni and Filomena Morisco and Elisabetta Bugianesi and Giovanni Targher and Amalia Gastaldelli and Fabio Piscaglia and Luca Valenti and Luca Miele and Amedeo Lonardo and Alessandro Casini and Mauro Bernardi",
year = "2017",
language = "English",
volume = "49",
pages = "471--483",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",

}

TY - JOUR

T1 - AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions

AU - Petta, Salvatore

AU - Bonino, Ferruccio

AU - Marra, Fabio

AU - Bellentani, Stefano

AU - Svegliati-Baroni, Gianluca

AU - Marchesini, Giulio

AU - Nascimbeni, Fabio

AU - Morisco, Filomena

AU - Bugianesi, Elisabetta

AU - Targher, Giovanni

AU - Gastaldelli, Amalia

AU - Piscaglia, Fabio

AU - Valenti, Luca

AU - Miele, Luca

AU - Lonardo, Amedeo

AU - Casini, Alessandro

AU - Bernardi, Mauro

PY - 2017

Y1 - 2017

N2 - This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic âhitsâ. The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed in-depth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (primary liver cancers and extra-hepatic cancers). Moreover, we critically report on the diagnostic role of non-invasive biomarkers, imaging techniques and liver biopsy, which remains the reference standard for diagnosing the disease, but cannot be proposed to all patients with suspected NAFLD. Finally, the management of NAFLD is also reviewed, by highlighting the lifestyle changes and the pharmacological options, with a focus on the innovative drugs. We conclude that the results of ongoing studies are eagerly expected to lead to introduce into the clinical arena new diagnostic and prognostic biomarkers, prevention and surveillance strategies as well as to new drugs for a tailored approach to the management of NAFLD in the individual patient.

AB - This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic âhitsâ. The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed in-depth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (primary liver cancers and extra-hepatic cancers). Moreover, we critically report on the diagnostic role of non-invasive biomarkers, imaging techniques and liver biopsy, which remains the reference standard for diagnosing the disease, but cannot be proposed to all patients with suspected NAFLD. Finally, the management of NAFLD is also reviewed, by highlighting the lifestyle changes and the pharmacological options, with a focus on the innovative drugs. We conclude that the results of ongoing studies are eagerly expected to lead to introduce into the clinical arena new diagnostic and prognostic biomarkers, prevention and surveillance strategies as well as to new drugs for a tailored approach to the management of NAFLD in the individual patient.

KW - Diagnosis

KW - Epidemiology

KW - Gastroenterology

KW - Genetics

KW - Hepatology

KW - Management

KW - Natural history

KW - Physiopathology

UR - http://hdl.handle.net/10447/248069

UR - http://www.elsevier.com/wps/find/journalbibliographicinfo.cws_home/623449/description#bibliographicinfo

M3 - Article

VL - 49

SP - 471

EP - 483

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

ER -